ALXN1007-APS-201 An Open-label proof of concept Phase IIa trial of ALXN1007 for the treatment of non-criteria manifestations of Antiphospholipid Syndrome

Administered By

Awarded By

Contributors

Start/End

  • July 1, 2014 - November 28, 2016